Rod-derived cone viability factor fusion protein
AssigneePharma Cinq, LLC
InventorsTianci LUO, Daniel LIPUT, Fong Qi LIANG
Life of this patent
Estimating the term…
Abstract
The present invention relates to a fusion protein comprising a) a short rod-derived cone viability factor (RdCVF-S), b) a hydrophilic peptide, and c) a signal peptide, along with the nucleic acids encoding those peptides and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting the fusion protein comprising RdCVF-S protein, an immunoglobulin constant region, and a human signal sequence, and methods of treatment.
Claims30
A fusion protein comprising a first N-terminal signal peptide, a second peptide C-terminal to the signal peptide, and a third peptide C-terminal to the second peptide;
- wherein the second peptide or the third peptide is an RdCVF-short peptide and the other is an immunoglobulin constant region.
6-34. (canceled)
A nucleic acid comprising a nucleotide sequence encoding a fusion protein comprising a first N-terminal signal peptide, a second peptide C-terminal to the signal peptide, and a third peptide C-terminal to the second peptide sequence;
- wherein the second peptide or the third peptide sequence is an RdCVF-short peptide sequence and the other is an immunoglobulin constant region sequence.
36-71. (canceled)
73-80. (canceled)
84-85. (canceled)
87-88. (canceled)
A fusion protein comprising a first N-terminal signal peptide, a second peptide C-terminal to the signal peptide, and a third peptide C-terminal to the second peptide;
- wherein the first peptide is a human immunoglobulin kappa chain (Igk) signal sequence;
- and
- wherein the second peptide or the third peptide is an RdCVF-short peptide and the other is a hydrophilic peptide.
91-127. (canceled)
129-133. (canceled)
135-142. (canceled)
146-147. (canceled)
149-150. (canceled)
Dependencies are inferred from the claim text.